Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003626 · ClinicalTrials.gov registry record · Phase 2
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
A Phase 2 study of Prostate Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Study locations
NCT00003626 is a Phase 2 study of Prostate Cancer that has completed, run by Barbara Ann Karmanos Cancer Institute. The trial reports 3 study locations across 3 states.
The verdict
NCT00003626, a Phase 2 study of Prostate Cancer, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic prostate cancer that has not responded to previous hormone therapy.
Conditions Studied
Interventions
- DRUG dolastatin 10
Study Locations (3)
Colorado
- University of Colorado Cancer Center - Denver
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-10 |
| Est. Completion | 2000-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003626
The ClinicalTrials.gov registry entry for NCT00003626 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which dolastatin 10 is the first listed.
NCT00003626 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00003626 about?
NCT00003626 is a clinical study titled "Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic prostate cancer that has not responded to previous hormone therapy.
What is the current status of trial NCT00003626?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-10. Estimated completion is 2000-05.
What conditions does trial NCT00003626 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00003626?
The interventions under investigation include: dolastatin 10 (DRUG).
Who is sponsoring clinical trial NCT00003626?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003626 being conducted?
This trial has 3 study locations across Colorado, Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.